title: Proposal of "cyclic therapy", a novel treatment strategy with targeted agents for advanced renal cell carcinoma.
abstract: The number of molecular targeted agents for advanced renal cell carcinoma (RCC) has gradually increased, but evidence on the optimal order of selection for such agents has not yet caught up with this trend. In addition, timing of switching molecular targeted drugs may also become an important issue for controlling the disease as types of these drugs grow in number. Based on the fact that the efficacy of a rechallenge of the drug previously used suggests the recovery of the sensitivity, a cyclic therapy in which drugs are changed before exacerbation to repeatedly administer several drugs in a rotated manner, may also be an effective sequential therapy.
authors.affiliation: Department of Urology, Kinki University Faculty of Medicine,377-2 Ohno-higashi, Osaka-sayama, 589-8511, Japan.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Nozawa
authors.affiliation: Department of Urology, Kinki University Faculty of Medicine,377-2 Ohno-higashi, Osaka-sayama, 589-8511, Japan.
authors.forename: Hirotsugu
authors.initials: H
authors.lastname: Uemura
keywords: Cyclic therapy; rechallenge; renal cell carcinoma (RCC); sequential therapy; targeted therapy
references.citation: Eur J Cancer. 2012 Feb;48(3):324-32
references.pmid: 21803569
references.citation: Clin Genitourin Cancer. 2009 Jan;7(1):24-7
references.pmid: 19213664
references.citation: Cancer. 2012 Apr 1;118(7):1868-76
references.pmid: 21898375
references.citation: N Engl J Med. 2007 Jan 11;356(2):115-24
references.pmid: 17215529
references.citation: Ann Oncol. 2012 Oct;23 Suppl 7:vii65-71
references.pmid: 22997456
references.citation: Cancer Invest. 2013 Jun;31(5):323-9
references.pmid: 23614653
references.citation: N Engl J Med. 2007 Jan 11;356(2):125-34
references.pmid: 17215530
references.citation: N Engl J Med. 2012 Mar 8;366(10):883-92
references.pmid: 22397650
references.citation: Lancet Oncol. 2011 Jul;12 (7):673-80
references.pmid: 21664867
references.citation: N Engl J Med. 2007 May 31;356(22):2271-81
references.pmid: 17538086
references.citation: Lancet. 2011 Dec 3;378(9807):1931-9
references.pmid: 22056247
references.citation: J Clin Oncol. 2009 Jul 10;27(20):3312-8
references.pmid: 19451442
references.citation: Cancer. 2010 Dec 1;116(23 ):5400-6
references.pmid: 21105118
references.citation: Lancet. 2008 Aug 9;372(9637):449-56
references.pmid: 18653228
references.citation: Future Oncol. 2010 Jun;6(6):897-900
references.pmid: 20528227
references.citation: Lancet Oncol. 2009 Aug;10 (8):757-63
references.pmid: 19615940
references.citation: BJU Int. 2012 Sep;110(6 Pt B):E228-34
references.pmid: 22332735
references.citation: J Clin Oncol. 2009 Aug 1;27(22):3584-90
references.pmid: 19487381
references.citation: Cancer. 2010 Mar 1;116(5):1272-80
references.pmid: 20082451